10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?

ABSTRACT:

Objectives

The German Pharmaceutical Market Restructuring Act (AMNOG, 2011) is a two-stage process to regulate the price of new pharmaceuticals in which price negotiations are conducted based on evidence-based medical benefit assessments using data from prior clinical trials. Although the act does not explicitly set a willingness-to-pay (WTP) threshold, the process itself implicitly establishes a WTP for health improvement. We evaluated the implicit WTP for prescription pharmaceuticals post-AMNOG in the German healthcare system from the decision-maker/payer perspective.

Methods

We extracted data on patient-group-specific annual treatment costs and endpoints from 2011 to 2021 from the dossiers assessed by the German Federal Joint Committee (FJC; Gemeinsamer Bundesausschuss).

SUBMITTER: Bussgen M 

PROVIDER: S-EPMC10227403 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature